Loading…
Makes guidewires and catheters used in cardiovascular and other minimally invasive medical procedures.
Makes guidewires and catheters used in cardiovascular and other minimally invasive medical procedures.
Sells guidewires and catheters both under its own Asahi brand and as components to larger device makers who sell them under their names, so some sales depend on those partners' volumes. Revenue rests on the number of procedures where a guidewire is used.
In one line: A specialized medical-device maker like a smaller Boston Scientific supplier.
Moat: narrow (process know-how, IP / patents). Precision wire-forming know-how for ultra-thin guidewires is difficult to replicate.
Headquarters: Nagoya, Japan · Founded: 1972 · Employees: 10,177
Size Asahi Intecc (7747.T) is a Japan Health Care company (Medical Specialties) with a market value of $6.28B, the 201st largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥3,734 on 6 Nov 2026.
Performance Over six months the shares gained 13.2%, against +27.7% for the median peer and +1.8% for the Japan market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 21.2% over the last twelve months (peer median +5.2%); the operating margin is 31.0% (peer median 13.9%).
Valuation It trades at 26.0× forward earnings against a peer median of 19.9× (5th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 14% a year for seven years (Req g). Recent delivered growth is +19%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 17.5 points above its cost of capital (8.5% WACC).
Next results Next results expected around 13 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | ¥145B | ¥145B | ¥120B | ¥108B | ¥90.1B |
| Revenue growth | — | +21% | +12% | +19% | — |
| Gross profit | ¥102B | ¥99.4B | ¥78.2B | ¥66.1B | ¥56.3B |
| EBITDA | ¥54.0B | ¥54.0B | ¥40.2B | ¥31.9B | ¥26.7B |
| Net income | ¥32.1B | ¥32.1B | ¥12.7B | ¥15.8B | ¥13.1B |
| Free cash flow | n/a | ¥31.7B | ¥32.4B | ¥24.8B | ¥6.85B |
| Capital expenditure | n/a | ¥8.93B | ¥8.58B | ¥10.5B | ¥12.7B |
| Total debt | ¥9.13B | ¥9.13B | ¥11.5B | ¥8.59B | ¥16.2B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Asahi Intecc 7747.T | $6.28B | +13% | +21% | 31% | 26.0× | 13.6% |
| Boston Scientific BSX | $62.0B | -21% | +9% | 21% | 13.8× | 5.0% |
| Medtronic MDT | $130B | +35% | +10% | 20% | 16.9× | 8.6% |
| Terumo 4543.T | $23.4B | +25% | +14% | 17% | 24.6× | 8.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7747.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +8.0% | +9.5% | 8th lowest of 21 |
| 6-month return | +13.2% | +27.7% | 4th lowest of 21 |
| Distance from 52-week high | -12.8% | -9.3% | 7th lowest of 21 |
| Revenue growth (TTM) | +21.2% | +5.2% | 4th highest of 21 |
| Operating margin | 31.0% | 13.9% | 4th highest of 21 |
| Forward P/E | 26.0× | 19.9× | 5th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 13.6% | 10.9% | 6th most demanding of 19 |
| Growth delivered (Del g) | +18.8% | +9.1% | 3rd highest of 19 |
| Hurdle (Req g minus delivered) | -5.2 pp | +1.6 pp | 5th least demanding of 19 |
| ROIC minus cost of capital | +17.5 pp | +3.1 pp | 3rd highest of 21 |
| EV / EBITDA | 17.4× | 14.1× | 5th most expensive of 17 |
| Net debt / EBITDA | -1.0× | 1.0× | 2nd least indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Asahi Intecc 7747.T | Japan | $6.28B | +13% | +21% | 31% | 26.0× | 13.6% | +18.8% |
| Ypsomed YPSN.SW | Switzerland | $6.35B | +30% | -2% | 25% | 30.1× | 11.5% | +12.6% |
| Teleflex TFX | United States | $6.39B | +13% | -14% | 11% | 16.8× | 17.8% | -4.7% |
| ConvaTec CTEC.L | United Kingdom | $6.44B | +22% | +2% | 16% | 16.7× | 15.6% | +4.6% |
| Lantheus LNTH | United States | $6.57B | +8% | +2% | 19% | 17.5× | -0.5% | +35.3% |
| APT Medical 688617.SS | China | $5.95B | +20% | +28% | 37% | 38.5× | 8.7% | +40.1% |
| Cochlear COH.AX | Australia | $7.05B | +55% | -1% | 13% | 29.4× | 24.1% | +9.3% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.11B | +25% | +7% | 43% | 25.5× | 2.1% | +15.7% |
| Bausch + Lomb BLCO.TO | Canada | $7.20B | +31% | +11% | 9% | 17.3× | 11.0% | +10.0% |
| Haemonetics HAE | United States | $5.46B | +118% | 0% | 18% | 21.6× | 10.9% | +8.9% |
| GRAIL GRAL | United States | $5.42B | +67% | +23% | -323% | n/a | n/a | n/a |
| Merit Medical Systems MMSI | United States | $5.23B | +42% | +9% | 14% | 19.4× | 12.2% | +9.5% |
| Getinge GETI-B.ST | Sweden | $7.73B | +45% | -4% | 14% | 21.0× | 4.7% | +3.2% |
| Shimadzu 7701.T | Japan | $7.79B | +15% | +6% | 13% | 19.5× | 6.3% | +7.3% |
| Sysmex 6869.T | Japan | $7.89B | +50% | +4% | 13% | 31.2× | 4.4% | +10.4% |
| DiaSorin DIA.MI | Italy | $5.00B | +19% | -3% | 24% | 20.6× | 4.1% | +6.3% |
| LivaNova LIVN | United States | $4.96B | +25% | +12% | 13% | 19.9× | 11.5% | +8.2% |
| MiniMed MMED | United States | $4.70B | +44% | +14% | 14% | 25.5× | n/a | n/a |
| Sotera Health SHC | United States | $4.57B | +1% | +7% | 37% | 15.4× | 13.7% | +7.3% |
| Intco Medical Technology 300677.SZ | China | $4.40B | -20% | +33% | 20% | 14.7× | -4.7% | -6.4% |
| ICU Medical ICUI | United States | $4.30B | +36% | -9% | 7% | 19.5× | 22.1% | +11.9% |